Patients in tissue kallikrein treatment group will be prescribed with intravenous infusion of tissue kallikrein ( 0.15 PNAU/d , dissolved in 100 ml saline ) for 7 days after stenting and then oral administration of pancreatic kallikrein enteric-coated tablet ( 240 U , 3/d ) to the end of study .